Category: Zacks Small Cap Research
By M. Marin OTC:NVNXF READ THE FULL NVNXF RESEARCH REPORT Novonix (OTC:NVNXF) is an integrated developer and supplier of high-performance materials, equipment and services for the global lithium-ion battery industry. Reflecting rising consumer adopt ...
By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT Fiscal Year 2020 Financial and Operational Review Tenax Therapeutics, Inc. (NASDAQ:TENX) reported fiscal year 2020, releasing results and filing Form 10-K with the SEC on Mar ...
By John Vandermosten, CFA NASDAQ:HTBX READ THE FULL HTBX RESEARCH REPORT Fourth Quarter and Fiscal Year 2020 Results Heat Biologics, Inc. (NASDAQ:HTBX) reported full year 2020 results on March 25, 2021 concurrent with the submission of Form 10-K t ...
By John Vandermosten, CFA NASDAQ:RVPH READ THE FULL RVPH RESEARCH REPORT Full Year 2020 Financial and Operational Results On March 22, 2021, Reviva Pharmaceutical Holdings, Inc. (NASDAQ:RVPH) announced full year 2020 financial and operational resu ...
By Steven Ralston, CFA NASDAQ:RKDA READ THE FULL RKDA RESEARCH REPORT Arcadia Biosciences (NASDAQ:RKDA) is on the cusp of meaningful revenue growth, primarily from management’s initiative into the hemp space, but also from the restructured strategi ...
By John Vandermosten, CFA NASDAQ:TLSA | LSE:TILS READ THE FULL TLSA RESEARCH REPORT In the fall of 2020, Tiziana Life Sciences PLC (NASDAQ:TLSA) (LSE:TILS) announced its intent to spin off its StemPrintER asset into a separate entity, Accustem Scie ...
By Lisa Thompson ="https:> NASDAQ:DUO READ THE FULL DUO RESEARCH REPORT Fangdd (NASDAQ:DUO) is working its way back to profitability from a pandemic-ravaged 2020 by cutting costs and introducing new higher margin services. Rather than matching su ...
By David Bautz, PhD NASDAQ:EPIXREAD THE FULL EPIX RESEARCH REPORT Business Update Additional Preclinical Data Presented at AACR 2021 On April 10, 2021, ESSA Pharma, Inc. (NASDAQ:EPIX) announced the presentation of encouraging preclinical data at ...
By John Vandermosten, CFA NASDAQ:TLSA | LSE:TILS READ THE FULL TLSA RESEARCH REPORT We are initiating coverage of Tiziana Life Sciences PLC (NASDAQ:TLSA) (LSE:TILS) with a current valuation of $7.50 per American Depository Receipt (ADR) share (1). ...
By David Bautz, PhD NYSE:OGEN READ THE FULL OGEN RESEARCH REPORT Business Update CoV-2 S-2P Demonstrates Protective Immunity in Mice In February 2021, Oragenics, Inc. (NYSE:OGEN) announced data from the National Institutes of Health (NIH) that de ...